Cargando…
The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer
PURPOSE: The status of the local and circulating SOX9, a master regulator of the tumor fate, and its relevance to tumor types, severity, invasion feature, response to therapy, and chemotherapy treatment were surveyed in bone cancer in the current study. METHODS: The SOX9 expression level was evaluat...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292907/ https://www.ncbi.nlm.nih.gov/pubmed/32551218 http://dx.doi.org/10.1016/j.jbo.2020.100300 |
_version_ | 1783546190787248128 |
---|---|
author | Hosseini, Ameinh Mirzaei, Alireza Salimi, Vahid Jamshidi, Khodamorad Babaheidarian, Pegah Fallah, Soudabeh Rampisheh, Zahra Khademian, Narges Abdolvahabi, Zohreh Bahrabadi, Mehrdad Ibrahimi, Mostafa Hosami, Fatemeh Tavakoli-Yaraki, Masoumeh |
author_facet | Hosseini, Ameinh Mirzaei, Alireza Salimi, Vahid Jamshidi, Khodamorad Babaheidarian, Pegah Fallah, Soudabeh Rampisheh, Zahra Khademian, Narges Abdolvahabi, Zohreh Bahrabadi, Mehrdad Ibrahimi, Mostafa Hosami, Fatemeh Tavakoli-Yaraki, Masoumeh |
author_sort | Hosseini, Ameinh |
collection | PubMed |
description | PURPOSE: The status of the local and circulating SOX9, a master regulator of the tumor fate, and its relevance to tumor types, severity, invasion feature, response to therapy, and chemotherapy treatment were surveyed in bone cancer in the current study. METHODS: The SOX9 expression level was evaluated in tissue and peripheral blood mononuclear cells from patients with different types of malignant and benign bone tumors also tumor margin tissues using Real-Time PCR. The protein level of SOX9 was assessed using immunohistochemistry and western blot analysis. Also, the correlations of the SOX9 expression level with the patient’s clinical and pathological features were considered. RESULTS: The remarkable overexpression of SOX9 was detected in bone tumors compared to tumor margin tissues (P < 0.0001). Malignant bone tumors revealed a higher expression of SOX9 compared to benign tumors (P < 0.0001) while osteosarcoma tumors showed higher expression levels compared to Ewing sarcoma, and chondrosarcoma. Overexpression of SOX9 was observed in high grade, metastatic, recurrent tumors also tumors with poor response to therapy. Besides, the patients under the chemotherapy treatment demonstrated higher levels of SOX9 compared to the rest of malignant tumors (P = 0.02). The simultaneous up-regulation of circulating SOX9 in the patients with bone cancer was observed compared to healthy individuals (P < 0.0001) accompanying with overexpression of SOX9 in malignant tumors compared to benign tumors (P < 0.0001). The circulating SOX9 expression was up-regulated in the patients with malignant bone tumors who receive chemotherapy treatment also patients with high grade, metastatic, recurrent tumors. The protein level of SOX9 was in line with our data on the SOX9 gene expression. CONCLUSION: The simultaneous overexpression of local and circulating SOX9 in bone cancer besides its positive correlation with tumor severity, malignancy, size, and chemotherapy may deserve receiving more attention in bone cancer diagnosis and therapy. |
format | Online Article Text |
id | pubmed-7292907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-72929072020-06-17 The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer Hosseini, Ameinh Mirzaei, Alireza Salimi, Vahid Jamshidi, Khodamorad Babaheidarian, Pegah Fallah, Soudabeh Rampisheh, Zahra Khademian, Narges Abdolvahabi, Zohreh Bahrabadi, Mehrdad Ibrahimi, Mostafa Hosami, Fatemeh Tavakoli-Yaraki, Masoumeh J Bone Oncol Research Article PURPOSE: The status of the local and circulating SOX9, a master regulator of the tumor fate, and its relevance to tumor types, severity, invasion feature, response to therapy, and chemotherapy treatment were surveyed in bone cancer in the current study. METHODS: The SOX9 expression level was evaluated in tissue and peripheral blood mononuclear cells from patients with different types of malignant and benign bone tumors also tumor margin tissues using Real-Time PCR. The protein level of SOX9 was assessed using immunohistochemistry and western blot analysis. Also, the correlations of the SOX9 expression level with the patient’s clinical and pathological features were considered. RESULTS: The remarkable overexpression of SOX9 was detected in bone tumors compared to tumor margin tissues (P < 0.0001). Malignant bone tumors revealed a higher expression of SOX9 compared to benign tumors (P < 0.0001) while osteosarcoma tumors showed higher expression levels compared to Ewing sarcoma, and chondrosarcoma. Overexpression of SOX9 was observed in high grade, metastatic, recurrent tumors also tumors with poor response to therapy. Besides, the patients under the chemotherapy treatment demonstrated higher levels of SOX9 compared to the rest of malignant tumors (P = 0.02). The simultaneous up-regulation of circulating SOX9 in the patients with bone cancer was observed compared to healthy individuals (P < 0.0001) accompanying with overexpression of SOX9 in malignant tumors compared to benign tumors (P < 0.0001). The circulating SOX9 expression was up-regulated in the patients with malignant bone tumors who receive chemotherapy treatment also patients with high grade, metastatic, recurrent tumors. The protein level of SOX9 was in line with our data on the SOX9 gene expression. CONCLUSION: The simultaneous overexpression of local and circulating SOX9 in bone cancer besides its positive correlation with tumor severity, malignancy, size, and chemotherapy may deserve receiving more attention in bone cancer diagnosis and therapy. Elsevier 2020-05-31 /pmc/articles/PMC7292907/ /pubmed/32551218 http://dx.doi.org/10.1016/j.jbo.2020.100300 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Hosseini, Ameinh Mirzaei, Alireza Salimi, Vahid Jamshidi, Khodamorad Babaheidarian, Pegah Fallah, Soudabeh Rampisheh, Zahra Khademian, Narges Abdolvahabi, Zohreh Bahrabadi, Mehrdad Ibrahimi, Mostafa Hosami, Fatemeh Tavakoli-Yaraki, Masoumeh The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer |
title | The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer |
title_full | The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer |
title_fullStr | The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer |
title_full_unstemmed | The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer |
title_short | The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer |
title_sort | local and circulating sox9 as a potential biomarker for the diagnosis of primary bone cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292907/ https://www.ncbi.nlm.nih.gov/pubmed/32551218 http://dx.doi.org/10.1016/j.jbo.2020.100300 |
work_keys_str_mv | AT hosseiniameinh thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT mirzaeialireza thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT salimivahid thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT jamshidikhodamorad thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT babaheidarianpegah thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT fallahsoudabeh thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT rampishehzahra thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT khademiannarges thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT abdolvahabizohreh thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT bahrabadimehrdad thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT ibrahimimostafa thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT hosamifatemeh thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT tavakoliyarakimasoumeh thelocalandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT hosseiniameinh localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT mirzaeialireza localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT salimivahid localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT jamshidikhodamorad localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT babaheidarianpegah localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT fallahsoudabeh localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT rampishehzahra localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT khademiannarges localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT abdolvahabizohreh localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT bahrabadimehrdad localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT ibrahimimostafa localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT hosamifatemeh localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer AT tavakoliyarakimasoumeh localandcirculatingsox9asapotentialbiomarkerforthediagnosisofprimarybonecancer |